| Previous Close | 39.240 |
| Open | 39.430 |
| Bid | 39.210 x 1500 |
| Ask | 39.220 x 1100 |
| Day's Range | 39.170 - 39.510 |
| 52 Week Range | 37.200 - 44.580 |
| Volume | 1,698,760 |
| Avg. Volume | 2,787,164 |
| Market Cap | 93.78B |
| Beta | 0.98 |
| PE Ratio (TTM) | 44.13 |
| EPS (TTM) | 0.89 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Dividend & Yield | 1.99 (5.09%) |
| Ex-Dividend Date | 2017-08-09 |
| 1y Target Est | 48.00 |
- Financial Times•3 hours ago
[$$] The questionable strategy of a pharmaceuticals CEO
Sir, Joining in the discussion about GlaxoSmithKline's new plans, I find chief executive Emma Walmsley's strategic thinking on research and development questionable. I suggest it shows the terrible consequences ...
- TheStreet.com•2 days ago
Shire Gains as it Seeks European Approval For Dry Eye Treatment
The drug would be the first such treatment in Europe.
- Financial Times•3 days ago
[$$] The key to innovation is balancing risk and rigour
Barely four months into her tenure as chief executive of GlaxoSmithKline, Emma Walmsley is showing her determination to focus the pharmaceutical company's research and development efforts. Having said ...
